Hcw Biologics INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
HCW Biologics Inc. is holding its 2026 Annual Meeting of Stockholders on June 15, 2026, to vote on director elections, auditor ratification, a reverse stock split, and warrant proposals.
NASDAQ
DEFA14A: HCW Biologics Inc. Sets Date for 2025 Annual Meeting, Outlines Proposals for Stockholder Vote
HCW Biologics Inc. announces its 2025 Annual Meeting of Stockholders to be held on June 17, 2025, with proposals including the election of directors and ratification of the company's independent registered public accounting firm.
NASDAQ
HCW Biologics Inc. announces its 2025 Annual Meeting of Stockholders to be held virtually on June 17, 2025, to elect directors and ratify the appointment of its independent accounting firm.
NASDAQ
HCW Biologics files an amendment to its proxy statement to correct a clerical error regarding the number of outstanding common shares.
NASDAQ
HCW Biologics is holding a special meeting to vote on proposals including a reverse stock split, an equity line of credit, and a note conversion to maintain its Nasdaq listing.
NASDAQ
HCW Biologics Inc. announces its annual stockholder meeting to be held virtually on June 14, 2024, with voting open until June 13, 2024.
NASDAQ
HCW Biologics Inc. will hold its 2024 Annual Meeting of Stockholders virtually on June 14, 2024, to elect a director and ratify the appointment of its independent accounting firm.